Loading clinical trials...
Loading clinical trials...
A Phase 1a/1b Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Conditions
Interventions
LY4066434.
Cetuximab
+10 more
Locations
56
United States
University of Alabama at Birmingham
Birmingham, Alabama, United States
Mayo Clinic
Phoenix, Arizona, United States
City of Hope
Duarte, California, United States
University of California, Los Angeles (UCLA)
Santa Monica, California, United States
University of Colorado Denver
Denver, Colorado, United States
Yale University School of Medicine - Yale Cancer Center
New Haven, Connecticut, United States
Start Date
October 21, 2024
Primary Completion Date
January 1, 2030
Completion Date
January 1, 2030
Last Updated
April 22, 2026
NCT07446322
NCT06043817
NCT02600949
NCT05919264
NCT06921928
NCT06423326
Lead Sponsor
Eli Lilly and Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions